Khan T. World Health Organization - Cardiovascular Diseases Overview. 2022.

Ganda OP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72:330–43.

Article  Google Scholar 

Libby P. Triglycerides on the rise: should we swap seats on the seesaw? Eur Heart J. 2014;36:774–6.

Article  Google Scholar 

• Tall AR, et al. Addressing dyslipidemic risk beyond LDL-cholesterol. The Journal of Clinical Investigation. 2022;132. (This review covers residual cardiovascular risk and the role triglycerides play, including current and novel therapies targeting triglycerides for event reduction.)

Collaboration* TERF. Major Lipids, Apolipoproteins, and Risk of Vascular Disease. JAMA. 2009;302:1993–2000.

Triglyceride-mediated pathways and coronary disease. collaborative analysis of 101 studies. The Lancet. 2010;375:1634–9.

Article  Google Scholar 

•• Mason RP, et al. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40:1135–47. (This review covers many of the biochemical differences between EPA and DHA and provides mechanistic insight into potential novel mechanisms of atheroprotection with EPA.)

Article  Google Scholar 

Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease. Circ Res. 2016;118:547–63.

Article  Google Scholar 

Burgess S, et al. Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions. PLoS ONE. 2014;9:e108891.

Article  Google Scholar 

Ference BA, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019;321:364–73.

Article  Google Scholar 

Hansen SEJ, et al. Low-Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population. Clin Chem. 2019;65:321–32.

Article  Google Scholar 

Mason RP, et al. Rationale for different formulations of omega-3 fatty acids leading to differences in residual cardiovascular risk reduction. Metabolism - Clinical and Experimental. 2022;130.

Mason RP, Eckel RH. Mechanistic Insights from REDUCE-IT STRENGTHen the Case Against Triglyceride Lowering as a Strategy for Cardiovascular Disease Risk Reduction. Am J Med. 2021;134:1085–90.

Article  Google Scholar 

Borow KM, et al. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242:357–66.

Article  Google Scholar 

Sherratt SCR, et al. A Biological Rationale for the Disparate Effects of Omega-3 Fatty Acids on Cardiovascular Disease Outcomes. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2022:102450.

Laufs U, et al. Clinical review on triglycerides. Eur Heart J. 2019;41:99–109c.

Article  Google Scholar 

Vallejo-Vaz AJ, et al. Triglycerides and residual risk. Curr Opin Endocrinol Diabetes Obes. 2020;27:95–103.

Article  Google Scholar 

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease. New England Journal of Medicine. 2014;371:22–31.

Bergmark BA, et al. Effect of Vupanorsen on Non-High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145:1377–86.

Article  Google Scholar 

Ionis Pharmaceuticals I. Pfizer and Ionis announce discontinuation of vupanorsen clinical development program. 2022.

Raal FJ, et al. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383:711–20.

Article  Google Scholar 

Rosenson RS, et al. Evinacumab in Patients with Refractory Hypercholesterolemia. N Engl J Med. 2020;383:2307–19.

Article  Google Scholar 

Witztum JL, et al. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. N Engl J Med. 2019;381:531–42.

Article  Google Scholar 

Onat UI, et al. Intercepting the Lipid-Induced Integrated Stress Response Reduces Atherosclerosis. J Am Coll Cardiol. 2019;73:1149–69.

Article  Google Scholar 

Zhao N, et al. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors. J Autoimmun. 2020;113:102515.

Article  Google Scholar 

Martínez GJ, et al. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018;269:262–71.

Article  Google Scholar 

• Duewell P, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357–61. (This study was the first to show direct evidence that the NLRP3 inflammasome can be activated by cholesterol crystals.)

Article  Google Scholar 

Ballantyne CM, et al. Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies. J Clin Lipidol. 2016;10:635-645.e1.

Article  Google Scholar 

Effects of combination lipid therapy in type 2 diabetes mellitus. New England Journal of Medicine. 2010;362:1563–1574.

Effects of extended-release niacin with laropiprant in high-risk patients. New England Journal of Medicine. 2014;371:203–212.

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. New England Journal of Medicine. 2011;365:2255–2267.

Pradhan AD, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80–93.

Article  Google Scholar 

Kowa Research Institute I. Kowa to discontine K-877 (pemafibrate) "PROMINENT" cardiovascular outcomes study. 2022.

Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids Health Dis. 2017;16:149.

Article  Google Scholar 

Shearer GC, et al. Fish oil — How does it reduce plasma triglycerides? Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2012;1821:843–51.

Article  Google Scholar 

Oh DY, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–98.

Article  Google Scholar 

Quesada-López T, et al. The lipid sensor GPR120 promotes brown fat activation and FGF21 release from adipocytes. Nat Commun. 2016;7:13479.

Article  Google Scholar 

Gotoh C, et al. The regulation of adipogenesis through GPR120. Biochem Biophys Res Commun. 2007;354:591–7.

Article  Google Scholar 

Xu HE, et al. Molecular Recognition of Fatty Acids by Peroxisome Proliferator-Activated Receptors. Mol Cell. 1999;3:397–403.

Article  Google Scholar 

Dubois V, et al. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. J Clin Investig. 2017;127:1202–14.

Article  Google Scholar 

Schoonjans K, et al. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 1996;15:5336–48.

Article  Google Scholar 

Grevengoed TJ, et al. An abundant biliary metabolite derived from dietary omega-3 polyunsaturated fatty acids regulates triglycerides. The Journal of Clinical Investigation. 2021;131.

•• Bhatt D, L., et al. Cardiovascular risk reduction with Icosapent Ethyl for hypertriglyceridemia. New England Journal of Medicine. 2019;380:11–22. (This is the original data manuscript of REDUCE-IT describing significant cardiovascular event reduction with icosapent ethyl.)

Olshansky B, et al. REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. Eur Heart J - Cardiovasc Pharm. 2020;7:e61–3.

Article  Google Scholar 

Peterson BE, et al. Reduction in Revascularization With Icosapent Ethyl. Circulation. 2021;143:33–44.

Article  Google Scholar 

Bhatt DL, et al. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. J Am Coll Cardiol. 2019;73:2791–802.

Article  Google Scholar 

Peterson BE, et al. Treatment with icosapent ethyl to reduce ischemic events in patients with prior percutaneous coronary intervention- insights from REDUCE-IT PCI. J Am Heart Assoc. 2022;11:e022937.

Article  Google Scholar 

Gaba P, et al. Prevention of ischemic events and mortality with icosapent ethyl in patients with prior myocardial infarction. Journal of the American College of Cardiology. 2022;In Press.

Verma S, et al. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation. 2021;144:1845–55.

Article  Google Scholar 

Majithia A, et al. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation. 2021;144:1750–9.

Article  Google Scholar 

Singh N, et al. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. J Am Coll Cardiol. 2022;79:220–2.

Article  Google Scholar 

Bhatt DL, et al. REDUCE-IT USA. Circulation. 2020;141:367–75.

Article  Google Scholar 

• Yokoyama M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. The Lancet. 2007;369:1090–8. (This is the original data manuscript of the JELIS trial, which showed significant cardiovascular event reduction in hypercholesterolemic patients with EPA ethyl ester added to statin therapy.)

Article  Google Scholar 

Saito Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008;200:135–40.

Article  Google Scholar 

Pisaniello AD, et al. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. European Medical Journal. 2020;5:29–36.

Google Scholar 

Watanabe T, et al. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins. J Cardiol. 2017;70:537–44.

Article  Google Scholar 

Nishio R, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234:114–9.

Article  Google Scholar 

• Budoff MJ, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41:3925–32. (The EVAPORATE trial provides mechanistic insight into the benefits of icospaent ethyl on atherosclerotic cardiovascular events, where plaque volume not only attenuated by also regressed.)

Article  Google Scholar 

Williams MC, et al. Low-Attenuation Noncalcified Plaque on Coronary Computed Tomography Angiography Predicts Myocardial Infarction. Circulation. 2020;141:1452–62.

Article  Google Scholar 

• Sato T, et al. Preferential Incorporation of Administered Eicosapentaenoic Acid Into Thin-Cap Atherosclerotic Plaques. Arterioscler Thromb Vasc Biol. 2019;39:1802–16. (This study showed that EPA preferntially incorporates into atherosclerotic plaques compared to DHA and other novel mechanisms of atheroprotection with EPA.)

Article  Google Scholar 

Cawood AL, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010;212:252–9.

Article  Google Scholar 

• Nicholls SJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324:2268–80. (The original data manuscript of the STRENGTH trial, showing no reduction of cardiovascular events with an EPA/DHA mixed formulation in a similar patient population as REDUCE-IT.)

Article  Google Scholar 

Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus. New England Journal of Medicine. 2018;379:1540–1550.

Manson JE, et al. Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2018;380:23–32.